Anti-Mullerian Hormone as Predictor of Ovarian Responce to Clomiphene Citrate in PCOS
Status:
Unknown status
Trial end date:
2018-12-01
Target enrollment:
Participant gender:
Summary
Polycystic ovary syndrome (PCOS) is found in 5% to 6% of women of reproductive age. It
affects women's reproductive capability; thus patients have risks of infertility,
miscarriage, and complicated pregnancy. A study revealed that the prevalence of
oligoovulation or anovulation in patients with PCOS ranged from 65% to 80%. Anti-Mullerian
Hormone (AMH) is an important regulator in the ovary that play a rule during development and
function. It is suspected to affect clomiphene citrate (cc) resistance. In this study the
investigator will assess the accuracy of AMH prediction of response to cc in women with PCOS.